SCHEMBL2854239

SCHEMBL2854239

NC(CCCCN1CCC(c2nc3ccccc3s2)CC1)C(=O)N1CCSC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.51
KMT2A Q03164 3/20 0.51
ALDH1A1 P00352 3/20 0.51
GAA P10253 1/20 0.51
LMNA P02545 4/20 0.47
HTR1A P08908 2/20 0.47
DRD2 P14416 2/20 0.47
HTR2A P28223 2/20 0.47
SLC6A4 P31645 2/20 0.47
HTR7 P34969 2/20 0.47
SLC6A2 P23975 1/20 0.47
HTR2C P28335 1/20 0.47
HRH1 P35367 1/20 0.47
DPP7 Q9UHL4 2/20 0.46
GALR3 O60755 1/20 0.46
HPGD P15428 1/20 0.46
DPP4 P27487 1/20 0.46
DPP8 Q6V1X1 1/20 0.46
DPP9 Q86TI2 1/20 0.46
MEN1 O00255 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2854236 1.00 SMN1; SMN2 (0.51) SMN1; SMN2KMT2AALDH1A1GAALMNA
SCHEMBL2856724 0.88 DPP7 (0.43) SMN1; SMN2KMT2AALDH1A1GAALMNA
SCHEMBL2856727 0.88 DPP7 (0.43) SMN1; SMN2KMT2AALDH1A1GAALMNA
SCHEMBL2854152 0.88 DPP7 (0.43) SMN1; SMN2KMT2AALDH1A1GAALMNA
SCHEMBL2854147 0.88 DPP7 (0.43) SMN1; SMN2KMT2AALDH1A1GAALMNA
SCHEMBL2849763 0.86 UBE2M (0.43) LMNADRD2DPP7DPP4DPP8
SCHEMBL2862012 0.86 DPP4 (0.45) SMN1; SMN2KMT2AALDH1A1GAASLC6A4
SCHEMBL2862006 0.86 DPP4 (0.45) SMN1; SMN2KMT2AALDH1A1GAASLC6A4
SCHEMBL2849768 0.86 UBE2M (0.43) LMNADRD2DPP7DPP4DPP8
SCHEMBL2857447 0.86 DRD2 (0.44) KMT2AALDH1A1LMNADRD2DPP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7790725-B2 Thiazolidine derivatives and medicinal use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-09-07 US disclosed
US-20070259880-A1 THIAZOLIDINE DERIVATIVES AND MEDICINAL USE THEREOF MITSUBISHI PHARMA CORPORATION (JP) 2007-11-08 US disclosed
CN-1606549-A Thiazolidine derivative and medical application thereof MITSUBISHI PHARMA CORP (JP) 2005-04-13 CN disclosed
EP-1426366-A1 THIAZOLIDINE DERIVATIVE AND MEDICINAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2004-06-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070259880-A1 THIAZOLIDINE DERIVATIVES AND MEDICINAL USE THEREOF DPP4, DPP7, DPP3 SMN1; SMN2 3494/4885KMT2A 1595/4885ALDH1A1 148/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.